NCT05363839View on ClinicalTrials.gov

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

PHASE1TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

November 2, 2022

Study Completion Date

November 2, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

ACH-000029

ACH-000029 will be administered orally via a capsule.

DRUG

Placebo

Placebo will be administered orally via a capsule.

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

lead

Syneos Health

OTHER